Kyorin Pharmaceutical Co., Ltd. - Product Pipeline Review - 2014

Published: Sep, 2014 | Pages: 61 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Kyorin Pharmaceutical Co., Ltd. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Kyorin Pharmaceutical Co., Ltd. - Product Pipeline Review - 2014', provides an overview of the Kyorin Pharmaceutical Co., Ltd.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Kyorin Pharmaceutical Co., Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Kyorin Pharmaceutical Co., Ltd. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Kyorin Pharmaceutical Co., Ltd.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Kyorin Pharmaceutical Co., Ltd.'s pipeline products

Reasons to buy

- Evaluate Kyorin Pharmaceutical Co., Ltd.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Kyorin Pharmaceutical Co., Ltd. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Kyorin Pharmaceutical Co., Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Kyorin Pharmaceutical Co., Ltd. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Kyorin Pharmaceutical Co., Ltd.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Kyorin Pharmaceutical Co., Ltd. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Kyorin Pharmaceutical Co., Ltd. Snapshot 6
Kyorin Pharmaceutical Co., Ltd. Overview 6
Key Information 6
Key Facts 6
Kyorin Pharmaceutical Co., Ltd. - Research and Development Overview 7
Key Therapeutic Areas 7
Kyorin Pharmaceutical Co., Ltd. - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Combination Treatment Modalities 12
Pipeline Products - Partnered Products 13
Partnered Products/Combination Treatment Modalities 14
Kyorin Pharmaceutical Co., Ltd. - Pipeline Products Glance 15
Kyorin Pharmaceutical Co., Ltd. - Late Stage Pipeline Products 15
Pre-Registration Products/Combination Treatment Modalities 15
Phase III Products/Combination Treatment Modalities 16
Kyorin Pharmaceutical Co., Ltd. - Clinical Stage Pipeline Products 17
Phase II Products/Combination Treatment Modalities 17
Phase I Products/Combination Treatment Modalities 18
Kyorin Pharmaceutical Co., Ltd. - Early Stage Pipeline Products 19
Preclinical Products/Combination Treatment Modalities 19
Kyorin Pharmaceutical Co., Ltd. - Unknown Stage Pipeline Products 20
Unknown Products/Combination Treatment Modalities 20
Kyorin Pharmaceutical Co., Ltd. - Drug Profiles 21
aclidinium bromide 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
(aclidinium bromide + formoterol fumarate) 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
ibudilast 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
KRP-203 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
KRPAM-1977X 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
neramexane mesylate 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
KRPAM-1977Y 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
AX-11890 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
AX-13057 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
KCA-1490 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Small Molecule to Inhibit PDE4 for Inflammation 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
tipelukast 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
MN-002 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Kyorin Pharmaceutical Co., Ltd. - Pipeline Analysis 40
Kyorin Pharmaceutical Co., Ltd. - Pipeline Products by Target 40
Kyorin Pharmaceutical Co., Ltd. - Pipeline Products by Route of Administration 42
Kyorin Pharmaceutical Co., Ltd. - Pipeline Products by Molecule Type 43
Kyorin Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action 44
Kyorin Pharmaceutical Co., Ltd. - Recent Pipeline Updates 46
Kyorin Pharmaceutical Co., Ltd. - Dormant Projects 55
Kyorin Pharmaceutical Co., Ltd. - Discontinued Pipeline Products 56
Discontinued Pipeline Product Profiles 56
KRP-104 56
KRP-105 56
KRP-110 56
tipelukast 56
Kyorin Pharmaceutical Co., Ltd. - Locations And Subsidiaries 57
Head Office 57
Other Locations & Subsidiaries 57
Appendix 60
Methodology 60
Coverage 60
Secondary Research 60
Primary Research 60
Expert Panel Validation 60
Contact Us 61
Disclaimer 61

List of Tables
Kyorin Pharmaceutical Co., Ltd., Key Information 6
Kyorin Pharmaceutical Co., Ltd., Key Facts 6
Kyorin Pharmaceutical Co., Ltd. - Pipeline by Indication, 2014 9
Kyorin Pharmaceutical Co., Ltd. - Pipeline by Stage of Development, 2014 10
Kyorin Pharmaceutical Co., Ltd. - Monotherapy Products in Pipeline, 2014 11
Kyorin Pharmaceutical Co., Ltd. - Combination Treatment Modalities in Pipeline, 2014 12
Kyorin Pharmaceutical Co., Ltd. - Partnered Products in Pipeline, 2014 13
Kyorin Pharmaceutical Co., Ltd. - Partnered Products/ Combination Treatment Modalities, 2014 14
Kyorin Pharmaceutical Co., Ltd. - Pre-Registration, 2014 15
Kyorin Pharmaceutical Co., Ltd. - Phase III, 2014 16
Kyorin Pharmaceutical Co., Ltd. - Phase II, 2014 17
Kyorin Pharmaceutical Co., Ltd. - Phase I, 2014 18
Kyorin Pharmaceutical Co., Ltd. - Preclinical, 2014 19
Kyorin Pharmaceutical Co., Ltd. - Unknown, 2014 20
Kyorin Pharmaceutical Co., Ltd. - Pipeline by Target, 2014 41
Kyorin Pharmaceutical Co., Ltd. - Pipeline by Route of Administration, 2014 42
Kyorin Pharmaceutical Co., Ltd. - Pipeline by Molecule Type, 2014 43
Kyorin Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action, 2014 45
Kyorin Pharmaceutical Co., Ltd. - Recent Pipeline Updates, 2014 46
Kyorin Pharmaceutical Co., Ltd. - Dormant Developmental Projects,2014 55
Kyorin Pharmaceutical Co., Ltd. - Discontinued Pipeline Products, 2014 56
Kyorin Pharmaceutical Co., Ltd., Other Locations 57
Kyorin Pharmaceutical Co., Ltd., Subsidiaries 59